Letrozol Medical Valley

Letrozole, the active ingredient in Letrozol Medical Valley, is an aromatase inhibitor presented as an oral tablet for oral use. The medication belongs to the antineoplastic hormone‑therapy class and works by reducing estrogen synthesis, thereby limiting the growth of hormone‑dependent breast tumours in postmenopausal women.

GNH USA supplies Letrozol Medical Valley as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozol Medical Valley, an aromatase inhibitor, is indicated for conditions driven by estrogen production. - Hormone receptor‑positive breast cancer (postmenopausal women): slows disease progression and reduces recurrence risk. - Adjuvant therapy after surgery: helps prevent cancer return when used in combination with other agents. - Neoadjuvant therapy before surgery: may shrink tumours to facilitate breast‑conserving procedures.

Letrozol Medical Valley may cause a range of adverse reactions.

Common Side Effects: - Hot flashes: transient feeling of warmth and sweating. - Joint or muscle pain: mild to moderate musculoskeletal discomfort. - Fatigue: reduced energy or tiredness. - Nausea: occasional upset stomach. - Headache: mild to moderate cranial pain. - Increased cholesterol: modest rise in blood lipid levels.

Serious or Rare Side Effects: - Osteoporosis or bone fractures: decreased bone mineral density. - Severe liver injury: marked elevation of hepatic enzymes. - Deep vein thrombosis or pulmonary embolism: clot formation in veins. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Cardiovascular events: hypertension or heart failure. - Vision changes: blurred vision or ocular discomfort.

When using Letrozol Medical Valley, consider the following safety measures. - Pregnancy avoidance: contraindicated in pregnancy (Category X); ensure effective contraception. - Menopause status: only indicated for postmenopausal patients; assess menopausal criteria before initiation. - Bone health monitoring: perform baseline and periodic bone density scans. - Liver function assessment: check hepatic enzymes prior to treatment and monitor regularly. - Drug interactions: review concomitant medications for potential CYP450 interactions. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Letrozol Medical Valley can interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce letrozole exposure. - Estrogen‑containing therapies (hormone replacement, oral contraceptives): antagonize therapeutic effect.

Moderate Interactions (Monitor Closely): - CYP2A6 inhibitors (e.g., fluvoxamine): may increase plasma concentrations. - Anticoagulants (warfarin): monitor INR as letrozole may affect clotting parameters. - Lipid‑lowering agents (statins): observe for altered lipid profiles. - Antidepressants (SSRIs): assess for additive fatigue or mood changes.